BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/26/2015 11:07:00 AM | Browse: 946 | Download: 930
Publication Name World Journal of Biological Chemistry
Manuscript ID 18703
Country/Territory Italy
Received
2015-04-27 11:11
Peer-Review Started
2015-04-28 08:25
To Make the First Decision
2015-05-14 16:45
Return for Revision
2015-05-19 09:28
Revised
2015-05-30 21:28
Second Decision
2015-07-09 08:42
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2015-07-23 16:51
Articles in Press
2015-07-23 16:51
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-08-11 13:27
Publish the Manuscript Online
2015-08-26 11:07
ISSN 1949-8454 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Current medical treatment of estrogen receptor-positive breast cancer
Manuscript Source Invited Manuscript
All Author List Franco Lumachi, Davide A Santeufemia and Stefano MM Basso
Funding Agency and Grant Number
Corresponding Author Franco Lumachi, MD, PsyD, Professor, Department of Surgery, Oncology and Gasteroenterology, University of Padua, School of Medicine, via Giustiniani 2, 35128 Padova, Italy. flumachi@unipd.it
Key Words Breast cancer; Endocrine therapy; GnRH-agonists; Ovarian function suppression; Tamoxifen; Selective estrogen receptor modulator; Aromatase inhibitors
Core Tip In women with breast cancer (BC), the two major endocrine therapies (ET) available are directed at blocking estrogen receptors (ERs) on cancer cells (selective estrogen receptor modulators), or against the key enzyme in the biosynthesis of estrogens (aromatase inhibitors). The new knowledge about molecular mechanisms regulating tumor progression, suggested the existence of a strict relationship between ERs, intracellular signaling pathways, and other growth factors receptor, which justify the escape of a portion of patients from the inhibitory effects of ET. To restore endocrine sensitivity of BC cells, molecular-target therapies are giving encouraging results, but further studies are required to confirm their real usefulness.
Publish Date 2015-08-26 11:07
Citation Lumachi F, Santeufemia DA, Basso SMM. Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem 2015; 6(3): 231-239
URL http://www.wjgnet.com/1949-8454/full/v6/i3/231.htm
DOI http://dx.doi.org/10.4331/wjbc.v6.i3.231
Full Article (PDF) WJBC-6-231.pdf
Full Article (Word) WJBC-6-231.doc
Manuscript File 1_Manuscript_18703_revised.doc
Answering Reviewers 2_Answering_Reviewers_18703.pdf
Copyright License Agreement 3_BPG_Copyright_Assignment_18703.pdf
Peer-review Report 18703-Peer-review(s).pdf
Scientific Editor Work List 18703-Scientific editor work list.pdf